Physician profile
Jonathan J King
NPI 1437447414
$1,256.55
in general payments reported to CMS, 2019-2025
22 companies · $421 in 2025
The $421 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.49 · 2020: $11.88 · 2021: $58.43 · 2022: $79.47 · 2023: $354 · 2024: $306 · 2025: $421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,081.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,081.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $376.33 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $175.97 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $66.10 | 2024-2025 | Caplyta |
| Myriad Women'S Health, INC. | $58.16 | 2023 | Myrisk |
| Exact Sciences Corporation | $49.79 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $48.37 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $45.59 | 2024-2025 | Mounjaro, Zepbound |
| Mylan Specialty L.P. | $45.04 | 2022 | |
| Biotissue Holdings INC. | $44.69 | 2024 | |
| Amgen INC. | $44.07 | 2024-2025 | Krystexxa |
| Phadia US INC. | $44.01 | 2023 | Immunocap |
| Astrazeneca Pharmaceuticals LP | $42.50 | 2023-2024 | Airsupra, Breztri |
| Boston Scientific Corporation | $36.01 | 2023 | |
| Verona Pharma, INC. | $29.36 | 2025 | Ohtuvayre |
| Otsuka America Pharmaceutical, INC. | $29.01 | 2025 | Rexulti |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $24.62 | 2025 | Keveyis |
| Gilead Sciences, INC. | $21.84 | 2025 | |
| Dexcom, INC. | $21.71 | 2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $18.15 | 2022 | |
| Melinta Therapeutics, LLC | $14.00 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.49 | 2019 | |
| Endogastric Solutions, INC | $9.74 | 2023 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.